Inference of Cellular Immune Environments in Sputum and Peripheral Blood Associated with Acute Exacerbations of COPD
- 3 Downloads
Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in the United States, with high associated costs. Most of the cost burden results from acute exacerbations of COPD (AE-COPD), events associated with heightened symptoms and mortality. Cellular mechanisms underlying AE-COPD are poorly understood, likely because they arise from dysregulation of complex immune networks across multiple tissue compartments.
To gain systems-level insight into cellular environments relevant to exacerbation, we applied data-driven modeling approaches to measurements of immune factors (cytokines and flow cytometry) measured previously in two different human tissue environments (sputum and peripheral blood) during the stable and exacerbated state.
Using partial least squares discriminant analysis, we identified a unique signature of cytokines in serum that differentiated stable and AE-COPD better than individual measurements. Furthermore, we found that models integrating data across tissue compartments (serum and sputum) trended towards being more accurate. The resulting paracrine signature defining AE-COPD events combined elevations of proteins associated with cell adhesion (sVCAM-1, sICAM-1) and increased levels of neutrophils and dendritic cells in blood with elevated chemoattractants (IP-10 and MCP-2) in sputum.
Our results supported a new hypothesis that AE-COPD is driven by immune cell trafficking into the lung, which requires expression of cell adhesion molecules and raised levels of innate immune cells in blood, with parallel upregulated expression of specific chemokines in pulmonary tissue. Overall, this work serves as a proof-of-concept for using data-driven modeling approaches to generate new insights into cellular processes involved in complex pulmonary diseases.
KeywordsSystems biology Inflammation Immune system Data-driven models Pulmonary disease
The authors would like to thank Lisa McCloskey, RRT, Christi Getty, RRT, and Candace Flaherty, RRT for interactions with subjects in the original study.
This work was supported by NIH R01 HL144849-01 (to K.B.A.). K.C.N. was supported by a Department of Education Graduate Assistance in Areas of National Need (GAANN) Fellowship awarded to the biomedical engineering department at the University of Michigan (PR Award Number: P200A150170). C.M.F. was supported by Merit Review Awards I01 CX001553 from the Department of Veterans Affairs and by MedImmune, Ltd. M.K.H. reports a grant from the National Heart, Lung and Blood Institute. F.J.M. has received grants from the National Institute of Health. J.L.C. was supported by Merit Review Awards I01 CX000911 from the Department of Veterans Affairs and by MedImmune, Ltd.
Conflict of interest
K.C.N., C.M.F., N.S.B, J.L.C. and K.B.A. reported no conflicts of interest. M.K.H. reports consultant arrangements with GlaxoSmithKline, Boehringer Ingelheim, Novartis, Sunovion, and AstraZeneca. F.J.M. has received personal fees from Forest, Janssen, GlaxoSmithKline, Nycomed/Takeda, Amgen, AstraZeneca, Boehringer Ingelheim, Ikaria/Bellerophon, Genentech, Novartis, Pearl, Pfizer, Roche, Sunovion, Theravance, Axon, CME Incite, California Society for Allergy and Immunology, Annenberg, Integritas, InThough, Miller Medical, National Association for Continuing Education, Paradigm, Peer Voice, UpToDate, Haymarket Communications, Western Society of Allergy and Immunology, Informa, Bioscale, Unity Biotechnology, ConCert, Lucid, Methodist Hospital, Prime, WebMD, Bayer, Ikaria, Kadmon, Vercyte, American Thoracic Society, Academic CME, Falco, Axon Communication, Johnson & Johnson, Clarion, Continuing Education, Potomac, Afferent, and Adept; and has collected nonfinancial support from Boehringer Ingelheim, Centocor, Gilead, and Biogen/Stromedix; and declares other interests with Mereo, Boehringering Ingelheim, and Centocor.
All human subjects research was carried out in accordance with the Declaration of Helsinki and were approved by the Institutional Review Boards of the Veterans’ Affairs Ann Arbor Healthcare System (VAAHS) and of the University of Michigan Health System (UMHS).
Research Involved in Human or animal rights
No animal studies were carried out by the authors for this article.
- 1.Aaron, C. P., J. E. Schwartz, S. J. Bielinski, E. A. Hoffman, J. H. M. Austin, E. C. Oelsner, K. M. Donohue, R. Kalhan, C. Berardi, J. D. Kaufman, D. R. Jacobs, R. P. Tracy, and R. G. Barr. Intercellular adhesion molecule 1 and progression of percent emphysema: The MESA Lung Study. Resp. Med. 109:255–264, 2015.CrossRefGoogle Scholar
- 2.Agouridakis, P., D. Kyriakou, M. G. Alexandrakis, A. Prekates, K. Perisinakis, N. Karkavitsas, and D. Bouros. The predictive role of serum and bronchoalveolar lavage cytokines and adhesion molecules for acute respiratory distress syndrome development and outcome. Resp. Res. 3:25–25, 2002.CrossRefGoogle Scholar
- 3.Agustí, A., L. D. Edwards, S. I. Rennard, W. MacNee, R. Tal-Singer, B. E. Miller, J. Vestbo, D. A. Lomas, P. M. A. Calverley, E. Wouters, C. Crim, J. C. Yates, E. K. Silverman, H. O. Coxson, P. Bakke, R. J. Mayer, B. Celli, and ECLIPSE Investigators. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS ONE 7:e37483–e37483, 2012.CrossRefGoogle Scholar
- 4.Albert, R. K., J. Connett, W. C. Bailey, R. Casaburi, J. A. D. Cooper, G. J. Criner, J. L. Curtis, M. T. Dransfield, M. K. Han, S. C. Lazarus, B. Make, N. Marchetti, F. J. Martinez, N. E. Madinger, C. McEvoy, D. E. Niewoehner, J. Porsasz, C. S. Price, J. Reilly, P. D. Scanlon, F. C. Sciurba, S. M. Scharf, G. R. Washko, P. G. Woodruff, N. R. Anthonisen, and C. C. R. Network. Azithromycin for prevention of exacerbations of COPD. New Engl. J. Med. 365:689–698, 2011.CrossRefGoogle Scholar
- 5.Andelid, K., A. Andersson, S. Yoshihara, C. Âhrén, P. Jirholt, A. Ekberg-Jansson, and A. Lindén. Systemic signs of neutrophil mobilization during clinically stable periods and during exacerbations in smokers with obstructive pulmonary disease. Int. J. Chronic Obstr. 10:1253–1263, 2015.Google Scholar
- 6.Arnold, K. B., A. Burgener, K. Birse, L. Romas, L. J. Dunphy, K. Shahabi, M. Abou, G. R. Westmacott, S. McCorrister, J. Kwatampora, B. Nyanga, J. Kimani, L. Masson, L. J. Liebenberg, S. S. Abdool Karim, J.-A. S. Passmore, D. A. Lauffenburger, R. Kaul, and L. R. McKinnon. Increased levels of inflammatory cytokines in the female reproductive tract are associated with altered expression of proteases, mucosal barrier proteins, and an influx of HIV-susceptible target cells. Mucosal Immunol. 9:194–205, 2016.CrossRefGoogle Scholar
- 7.Bafadhel, M., S. McKenna, S. Terry, V. Mistry, C. Reid, P. Haldar, M. McCormick, K. Haldar, T. Kebadze, A. Duvoix, K. Lindblad, H. Patel, P. Rugman, P. Dodson, M. Jenkins, M. Saunders, P. Newbold, R. H. Green, P. Venge, D. A. Lomas, M. R. Barer, S. L. Johnston, I. D. Pavord, and C. E. Brightling. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am. J. Resp. Crit. Care 184:662–671, 2011.CrossRefGoogle Scholar
- 20.Freeman, C. M., and J. L. Curtis. Lung dendritic cells: shaping immune responses throughout COPD progression. Am. J. Resp. Cell Mol. 56:152–159, 2017.Google Scholar
- 21.Freeman, C. M., F. J. Martinez, M. K. Han, T. M. Ames, S. W. Chensue, J. C. Todt, D. A. Arenberg, C. A. Meldrum, C. Getty, L. McCloskey, and J. L. Curtis. Lung dendritic cell expression of maturation molecules increases with worsening chronic obstructive pulmonary disease. Am. J. Resp. Crit. Care 180:1179–1188, 2009.CrossRefGoogle Scholar
- 22.Freeman, C. M., C. H. Martinez, J. C. Todt, F. J. Martinez, M. K. Han, D. L. Thompson, L. McCloskey, and J. L. Curtis. Acute exacerbations of chronic obstructive pulmonary disease are associated with decreased CD4+ & CD8+ T cells and increased growth & differentiation factor-15 (GDF-15) in peripheral blood. Resp. Res. 16:94–94, 2015.CrossRefGoogle Scholar
- 25.Halpin, D. M. G., M. Miravitlles, N. Metzdorf, and B. Celli. Impact and prevention of severe exacerbations of COPD: a review of the evidence. Int. J. Chronic. Obstr. 2891–2908:2017, 2017.Google Scholar
- 29.Johannesdottir, S. A., C. F. Christiansen, M. B. Johansen, M. Olsen, X. Xu, J. M. Parker, N. A. Molfino, T. L. Lash, and J. P. Fryzek. Hospitalization with acute exacerbation of chronic obstructive pulmonary disease and associated health resource utilization: a population-based Danish cohort study. J. Med. Econ. 16:897–906, 2013.CrossRefGoogle Scholar
- 31.Kochanek, K. D., S. Murphy, J. Xu, and E. Arias. Mortality in the United States, 2016. NCHS Data Brief 1–8, 2017.Google Scholar
- 34.Lau, K. S., A. M. Juchheim, K. R. Cavaliere, S. R. Philips, D. A. Lauffenburger, and K. M. Haigis. In vivo systems analysis identifies spatial and temporal aspects of the modulation of TNF-α-induced apoptosis and proliferation by MAPKs. Sci. Signal. 4:ra16, 2011.Google Scholar
- 35.Leeuwenberg, J. F., E. F. Smeets, J. J. Neefjes, M. A. Shaffer, T. Cinek, T. M. Jeunhomme, T. J. Ahern, and W. A. Buurman. E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. Immunology 77:543–549, 1992.Google Scholar
- 36.Liu, M., S. Guo, J. M. Hibbert, V. Jain, N. Singh, N. O. Wilson, and J. K. Stiles. CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications. Cytokine Growth Factor Rev. 22:121–130, 2011.Google Scholar
- 37.Martinez, F. J., P. M. A. Calverley, U.-M. Goehring, M. Brose, L. M. Fabbri, and K. F. Rabe. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet 385:857–866, 2015.CrossRefGoogle Scholar
- 40.Miller, B. E., R. Tal-Singer, S. I. Rennard, A. Furtwaengler, N. Leidy, M. Lowings, U. J. Martin, T. R. Martin, D. D. Merrill, J. Snyder, J. Walsh, and D. M. Mannino. Plasma fibrinogen qualification as a drug development tool in chronic obstructive pulmonary disease. Perspective of the chronic obstructive pulmonary disease biomarker qualification consortium. Am. J. Resp. Crit. Care 193:607–613, 2016.CrossRefGoogle Scholar
- 41.Mishra, A., Y. Guo, L. Zhang, S. More, T. Weng, N. R. Chintagari, C. Huang, Y. Liang, S. Pushparaj, D. Gou, M. Breshears, and L. Liu. A critical role for P2X7 receptor-induced VCAM-1 shedding and neutrophil infiltration during acute lung injury. J. Immunol. 197:2828–2837, 2016.CrossRefGoogle Scholar
- 44.O’Dwyer, D. N., K. C. Norman, M. Xia, Y. Huang, S. J. Gurczynski, S. L. Ashley, E. S. White, K. R. Flaherty, F. J. Martinez, S. Murray, I. Noth, K. B. Arnold, and B. B. Moore. The peripheral blood proteome signature of idiopathic pulmonary fibrosis is distinct from normal and is associated with novel immunological processes. Sci. Rep. 7:46560–46560, 2017.CrossRefGoogle Scholar
- 50.Röpcke, S., O. Holz, G. Lauer, M. Müller, S. Rittinghausen, P. Ernst, G. Lahu, M. Elmlinger, N. Krug, and J. M. Hohlfeld. Repeatability of and relationship between potential COPD biomarkers in bronchoalveolar lavage, bronchial biopsies, serum, and induced sputum. PLoS ONE 7:e46207–e46207, 2012.CrossRefGoogle Scholar
- 54.Vaitkus, M., S. Lavinskiene, D. Barkauskiene, K. Bieksiene, J. Jeroch, and R. Sakalauskas. Reactive oxygen species in peripheral blood and sputum neutrophils during bacterial and nonbacterial acute exacerbation of chronic obstructive pulmonary disease. Inflammation 36:1485–1493, 2013.CrossRefGoogle Scholar
- 56.Witkowska, A. M., and M. H. Borawska. Soluble intercellular adhesion molecule-1 (sICAM-1): an overview. Eur. Cytokine Netw. 15:91–98, 2004.Google Scholar
- 57.Wold, S., E. Johansson, and M. Cocchi. PLS-partial least squares projections to latent structures. In: 3D QSAR in Drug Design: Theory Methods and Applications, edited by H. Kubinyi. Dordrecht: Escom, 1993, pp. 523–550.Google Scholar
- 59.Yung S. C. and J. M. Farber. Chemokines. edited by A. J. KastinElsevier, pp. 656–663, 2013.Google Scholar